EndoC βH5 Human Beta Cells in T1 and T2 Diabetes Models 1

In this webinar, the speakers will talk about the contribution and convenience of in vitro human cell assays using primary-like human beta cells and associated tools for diabetes research. Optimized physiological, functional, and pharmacologically predictive in vitro models have the potential to accelerate drug discovery and development, prompting safer and more efficient drugs.

EndoC-βH5 cells are a recently established human beta-cell model. These cells represent a unique storable and ready-to-use tool with highly robust and reproducible features. This model, when exposed to different stimuli is thus relevant for the study of beta-cell function, screening and validation of new drugs, and development of disease models.

As an example, glucose stimulation of the EndoC-βH5 cells will result in the secretion of insulin in a dynamic manner and this secretion can be enhanced by GLP-1 (glucagon‐like peptide) and GIP (glucose‐dependent insulinotropic polypeptide) analogs. In this way, EndoC-βH5 based disease models for T1 and T2 diabetes, allow lead identification and optimization in drug development without compromising highly reproducible results and providing an accurate understanding of beta-cell function. Thus, showing that EndoC-βH5 cells can grant relevant early drug discovery through beta-cell function characterization and target identification and validation approaches.

Join us as we discuss existing models and solutions for biomedical research and drug development in diabetes based on the newly developed EndoC-βH5 primary-like human beta cells, which combine robust glucose-stimulated insulin secretion and GLP-1/GIP receptor activities and modeling of human T1 & T2 diabetes.